BRKR
NASDAQBruker Corporation
SectorIndustrialsIndustryBiotechnology: Laboratory Analytical Instruments
Price$36.27-2.70 (-6.94%)
01:15 PM07:45 PM
News · 26 weeks66+333%
2025-10-262026-04-19
Mix4390d
- Other15(35%)
- Insider15(35%)
- SEC Filings9(21%)
- Earnings2(5%)
- Dividends1(2%)
- Leadership1(2%)
Latest news
25 items- PRBruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026Bruker Spatial Biology features new GeoMx-to-CellScape and CellScape-to-CosMx cross-platform workflows and first-of-its-kind 208-plex CellScape XR spatial proteomics datasets Bruker Corporation (NASDAQ:BRKR) today announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Research (AACR) Annual Meeting. At AACR, Bruker Spatial Biology will highlight how its high-fidelity spatial platforms—designed to work together—deliver deeper insights into oncology biology and accelerate translational research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260417773444/en/PaintScape in sit
- PRBruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division ((Bruker Corporation, NASDAQ:BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the successful medium-throughput BeGenius® system, which excels at assay and sample matrix flexibility, the new higher-throughput MyGenius PRO® automates the entire workflow - from patient sample to diagnostic result - e
- PRBruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak ManagementMALDI Biotyper® (MBT): Launch of proprietary MBT Easy T® Kit for consistent sample transfer to MALDI target plates MALDI Biotyper®: Expansion of reference libraries to more than 5,300 species, spanning bacteria, yeasts, filamentous fungi, and mycobacteria MALDI Biotyper®: Early KOL access to a novel cloud‑based identification solution, enabling identification against several specialist, expert‑curated libraries MALDI Biotyper®: Ongoing broad, multi‑year clinical and translational study programs advancing automation, potential future claims, and next‑generation analytics, including: IVDR-compliant clinical validation studies evaluating automated sample preparation workflows, cove
- INSIDERSEC Form 4 filed by Munch Mark4 - BRUKER CORP (0001109354) (Issuer)
- PRBruker Unveils New NMR Products and Workflow Solutions at ENC 2026Introductions span console electronics, quantitative NMR software, 80 MHz benchtop FT‑NMR, solid‑state and dissolution DNP, and automated protein and RNA workflows. At the Experimental Nuclear Magnetic Resonance Conference (ENC), Bruker Corporation (NASDAQ:BRKR) today announced new NMR products and workflow solutions designed to expand performance, sensitivity, and automation across research and applied NMR. The introductions span console electronics, quantitative chemistry, benchtop FT-NMR, solid-state and dissolution Dynamic Nuclear Polarization (DNP), and digital workflows that support reproducible, unattended, and data-driven automation. This press release features multimedia. View t
- SECSEC Form DEFA14A filed by Bruker CorporationDEFA14A - BRUKER CORP (0001109354) (Filer)
- SECSEC Form DEF 14A filed by Bruker CorporationDEF 14A - BRUKER CORP (0001109354) (Filer)
- INSIDERSEC Form 3 filed by new insider Bernard Thierry3 - BRUKER CORP (0001109354) (Issuer)
- SECBruker Corporation filed SEC Form 8-K: Leadership Update8-K - BRUKER CORP (0001109354) (Filer)
- PRBruker Invests in Photothermal AFM-IR to Advance Semiconductor ResearchDimension IconIR to Support Critical Materials Characterization for Next-Generation Semiconductor Devices Bruker Corporation (NASDAQ:BRKR) today announced accelerated development of its photothermal AFM-IR spectroscopy capabilities to address research challenges facing the semiconductor industry as device architectures continue to shrink and systems become increasingly more complex. As the largest supplier of nanoscale infrared (nanoIR) spectroscopy technology to the semiconductor industry, Bruker is expanding the use of AFM-IR beyond its established role in nanoscale contamination analysis into research areas that underpin next-generation semiconductor technologies. These include EUV ph
- SECBruker Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - BRUKER CORP (0001109354) (Filer)
- PRBruker Announces Appointment of Thierry Bernard to its Board of DirectorsBruker Corporation (NASDAQ:BRKR) announces the appointment of Mr. Thierry L. Bernard to serve on its Board of Directors, effective as of today. Mr. Bernard is an international life-science tools and diagnostics industry executive with decades of relevant leadership, strategic and operational experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401348395/en/Thierry Bernard Frank H. Laukien, the Chairman, President and CEO of Bruker Corporation, stated: "Bruker is delighted that Thierry is joining our Board. I have admired his successful track record, astute strategic initiatives, and outstanding execution for many years,
- PRPreOmics GmbH and Biognosys AG Prevail in U.S. Patent ChallengeUS PTAB Revokes Sole Independent and Other Central Claims of U.S. Patent 11,435,360 PreOmics GmbH and Biognosys AG today announced a favorable outcome in an inter partes review (IPR) proceeding IPR2024‑01473 before the U.S. Patent Trial and Appeal Board (PTAB). The PTAB has revoked the central claims of U.S. Patent No. 11,435,360, which is owned by The Brigham and Women's Hospital, and exclusively licensed to Seer, Inc. The USPTO struck down the sole independent claim of the ‘360 patent, among other claims. The PTAB specifically invalidated Claim 1, which attempted to cover workflows using multiple nanoparticle types to form biomolecule coronas and detect proteins across a wide dynamic
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bruker CorporationSCHEDULE 13G/A - BRUKER CORP (0001109354) (Subject)
- INSIDEREXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19 and sold $70,880 worth of shares (2,000 units at $35.44) (SEC Form 4)4 - BRUKER CORP (0001109354) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bruker CorporationSCHEDULE 13G/A - BRUKER CORP (0001109354) (Subject)
- SECSEC Form S-8 POS filed by Bruker CorporationS-8 POS - BRUKER CORP (0001109354) (Filer)
- SECSEC Form S-8 filed by Bruker CorporationS-8 - BRUKER CORP (0001109354) (Filer)
- SECSEC Form 10-K filed by Bruker Corporation10-K - BRUKER CORP (0001109354) (Filer)
- PRBruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XRThe new platform delivers unmatched quantitation, robustness, and throughput to support clinical translation of spatial proteomics assays Bruker Corporation (NASDAQ:BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the development of diagnostic and prognostic assays by delivering unprecedented quantitative performance, robustness, and flexibility. CellScape XR addresses a critical bottleneck in translational research by enabling high-throughput, reproducible spatial proteomics at a scale and rigor required for translational and clinical applications. As spatial proteomics moves from discovery to translational research and to d
- PRBruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic ApplicationsBruker Spatial Biology, a division of Bruker Corporation (NASDAQ:BRKR) announced today that it will expand its collaboration with Noetik Inc., following their prior study of more than 3500 patient samples with the CosMx® Spatial Molecular Imager (SMI). CosMx SMI powers Noetik's pre-training and scaling of bio-foundation models to perform complex genome-wide simulations of human cellular- and tissue-level biology to enable diverse therapeutics applications. "Noetik's multiple spatial AI models, including the Oncology Counterfactual Therapeutics Oracle virtual cell, which can simulate patient biology and inform drug discovery, represent transformative breakthroughs for tackling human diseas
- PRBruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological SpectrumPortfolio innovations include the launch of the new CellScape XR spatial proteomics platform, the unique CosMx mouse whole transcriptome panel, the launch of the PaintScape platform for 3D genome visualization, extensive multiomics GeoMx capabilities, and AI-ready AtoMx analysis Bruker Corporation (NASDAQ:BRKR) announced today significant portfolio advancements from Bruker Spatial Biology to be unveiled at the 2026 Advances in Genome Biology and Technology (AGBT) General Meeting. These updates highlight Bruker's category leadership in spatial biology and its commitment to delivering best‑in‑class solutions across DNA, RNA, and protein. The Bruker Spatial Biology division will launch sever
- PRBruker Advances Functional Proteomics 2.0 with timsOmniTM Mass Spectrometry Proteoform Analysis for Deeper Insights into Disease BiologyNovel timsOmni™ workflows enable deeper functional characterization of proteoforms and PTMs, leveraging multi-stage, ultra-sensitive trapped eXd molecular fragmentation Bruker ProteoScape™ expands AI‑enhanced de novo peptide sequencing for complex samples from metaproteomics to immunopeptidomics timsOmni provides a powerful new ‘lamp post' for illuminating many complex molecular, pathway and mechanism of action dark areas in drug discovery and development Bruker Corporation (NASDAQ:BRKR) today announced new advancements to enable Functional Proteomics 2.0 workflows on the timsOmni™ mass spectrometer to enable disease researchers to move beyond canonical protein lists toward biolog
- SECBruker Corporation filed SEC Form 8-K: Leadership Update, Other Events8-K - BRUKER CORP (0001109354) (Filer)
- INSIDERDirector Francis Laura was granted 4,520 shares, increasing direct ownership by 100% to 9,018 units (SEC Form 4)4 - BRUKER CORP (0001109354) (Issuer)